LMR Partners’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$47.2M Buy
301,200
+246,200
+448% +$36.9M 0.18% 123
2026
Q1
$8.4M Sell
55,000
-34,700
-39% -$5.32M 0.02% 482
2025
Q4
$12.4M Buy
89,700
+22,300
+33% +$2.92M 0.02% 308
2025
Q3
$8.64M Hold
67,400
0.04% 368
2025
Q2
$8.16M Buy
67,400
+18,700
+38% +$2.11M 0.06% 327
2025
Q1
$5.43M Buy
+48,700
New +$5.18M 0.05% 378

Other funds holding NVS

LMR Partners's NVS Position: Q2 2026 in Review

LMR Partners increased its Novartis (NVS) stake by 257% in Q2 2026, buying an estimated $16.6M and bringing the position to 153,726 shares worth $24.1M. The position accounts for 0.09% of the portfolio, ranked #202.

LMR Partners first reported a position in NVS in Q2 2023 and has held it in 3 quarters since. 1,623 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • LMR Partners held 153,726 shares of Novartis worth $24.1M as of Q2 2026.
  • LMR Partners bought 110,621 Novartis shares in Q2 2026, an estimated $16.6M.
  • Novartis made up 0.09% of LMR Partners's portfolio in Q2 2026, its #202 holding.
  • LMR Partners first reported a position in Novartis in Q2 2023 and has held it in 3 quarters since.
  • 1,623 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.